TDMS Study 05063-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
PHENYLBUTAZONE
NTP Experiment-Test: 05063-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/08/94
Route: GAVAGE Time: 21:11:03
Facility: TSI Mason Research
Chemical CAS #: 50-33-9
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 20 11 5
Natural Death 8 9 12
Dead 1
Accident 1
Survivors
Terminal Sacrifice 22 29 32
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (44) (28) (47)
Intestine Large, Cecum (50) (8) (40)
Intestine Small, Ileum (46) (15) (44)
Intestine Small, Jejunum (49) (15) (45)
Liver (50) (49) (50)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 3 (6%) 4 (8%) 4 (8%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%) 3 (6%)
Mesentery (9) (8) (4)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Sarcoma, Metastatic, Skin 1 (11%)
Pancreas (50) (19) (49)
Pharynx (1)
Salivary Glands (48) (16) (49)
Stomach, Forestomach (50) (16) (48)
Squamous Cell Carcinoma, Early Invasion 2 (4%)
Squamous Cell Papilloma 3 (6%) 2 (4%)
Stomach, Glandular (49) (16) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (16) (50)
Carcinoma, Metastatic, Lung 1 (6%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (48) (15) (49)
Adrenal Gland, Cortex (48) (15) (49)
Adrenal Gland, Medulla (47) (15) (48)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (44) (17) (47)
Pars Distalis, Adenoma 8 (18%) 5 (29%) 3 (6%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (48) (14) (50)
Follicular Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (47) (47)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Luteoma 1 (2%)
Uterus (50) (49) (48)
Adenocarcinoma 2 (4%)
Hemangioma 1 (2%)
Leiomyoma 1 (2%) 1 (2%)
Polyp Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (15) (50)
Sternal, Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node (47) (24) (48)
Inguinal, Carcinoma, Metastatic, Lung 1 (4%)
Lumbar, Adenocarcinoma, Metastatic, Uterus 1 (4%)
Mediastinal, Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (34) (12) (30)
Lymph Node, Mesenteric (42) (18) (41)
Spleen (50) (29) (49)
Hemangiosarcoma 1 (3%)
Thymus (37) (11) (39)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (31) (5) (23)
Adenocarcinoma 1 (4%)
Skin (49) (16) (48)
Hemangioma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (6%) 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (16) (50)
Carcinoma, Metastatic, Lung 1 (6%)
Sternum, Fibrosarcoma, Deep Invasion 1 (6%)
Skeletal Muscle (2) (4) (4)
Sarcoma, Extension 1 (50%)
Hindlimb, Carcinoma, Metastatic, Lung 1 (25%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (16) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (21) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 2 (10%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 1 (5%)
Sarcoma, Metastatic, Skin 1 (2%)
Nose (50) (12) (41)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (1) (1)
Adenoma 1 (50%)
Lacrimal Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Carcinoma, Metastatic, Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Ureter (1)
Page 4
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Urinary Bladder (50) (16) (48)
Fibrosarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia 1 (2%)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 2 (4%) 1 (2%)
Lymphoma Malignant Mixed 2 (4%) 5 (10%) 4 (8%)
Lymphoma Malignant Undifferentiated Cell 7 (14%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 31 20 25
Total Primary Neoplasms 43 30 31
Total Animals with Benign Neoplasms 20 13 15
Total Benign Neoplasms 24 15 19
Total Animals with Malignant Neoplasms 17 12 12
Total Malignant Neoplasms 19 15 12
Total Animals with Metastatic Neoplasms 1 2 1
Total Metastatic Neoplasm 4 6 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 12 6 11
Natural Death 2 2 3
Accident 2
Survivors
Terminal Sacrifice 35 40 36
Natural Death 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (49) (5) (50)
Intestine Small, Ileum (49) (9) (50)
Intestine Small, Jejunum (49) (3) (49)
Liver (50) (50) (50)
Adenoma, Multiple 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatocellular Carcinoma 8 (16%) 3 (6%) 11 (22%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 6 (12%) 9 (18%) 15 (30%)
Hepatocellular Adenoma, Multiple 2 (4%) 3 (6%) 8 (16%)
Salivary Glands (50) (4) (50)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Stomach, Forestomach (48) (5) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (5) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (5) (50)
Hepatocellular Carcinoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (8) (48)
Adenoma 1 (2%)
Pituitary Gland (47) (5) (45)
Pars Distalis, Adenoma 1 (2%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Page 7
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (48) (5) (49)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1) (1) (11)
Adenocarcinoma 1 (100%)
Preputial Gland (10) (14) (8)
Basosquamous Tumor NOS 1 (10%)
Squamous Cell Carcinoma 1 (7%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (50) (27) (50)
Lymph Node, Mandibular (27) (1) (23)
Lymph Node, Mesenteric (45) (20) (47)
Spleen (50) (20) (50)
Hemangiosarcoma 1 (5%)
Thymus (41) (4) (34)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (11) (49)
Squamous Cell Carcinoma 1 (9%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (9%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 3 (6%) 2 (18%) 7 (14%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (33) (50)
Scapula, Osteosarcoma 1 (2%)
Skeletal Muscle (2)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (5) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (14) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 5 (36%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (7%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic 4 (8%) 4 (8%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1)
Fibrosarcoma 1 (100%)
Eye (2)
Lids, Fibrosarcoma, Metastatic, Ear 1 (50%)
Harderian Gland (3) (2) (3)
Adenoma 2 (67%) 1 (50%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50)
Renal Tubule, Hepatocellular Carcinoma,
Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 2 (4%) 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 4 (8%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 3 (6%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05063-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 21:11:03
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.15G/KG 0.3 G/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 30 28 40
Total Primary Neoplasms 42 39 57
Total Animals with Benign Neoplasms 17 17 30
Total Benign Neoplasms 20 20 35
Total Animals with Malignant Neoplasms 18 17 21
Total Malignant Neoplasms 21 19 22
Total Animals with Metastatic Neoplasms 5 4
Total Metastatic Neoplasm 5 7
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------